Investigator initiated trials versus industry sponsored trials-translation of randomized controlled trials into clinical practice (IMPACT)

被引:13
作者
Bluemle, Anette [1 ,2 ,3 ,4 ]
Wollmann, Katharina [1 ,2 ]
Bischoff, Karin [1 ,2 ]
Kapp, Philipp [1 ,2 ]
Lohner, Szimonetta [5 ]
Nury, Edris [1 ,2 ]
Nitschke, Kai [1 ,2 ]
Zaehringer, Jasmin [1 ,2 ]
Ruecker, Gerta [6 ,7 ]
Schumacher, Martin [6 ,7 ]
机构
[1] Univ Freiburg, Fac Med, Inst Evidence Med, Cochrane Germany Fdn, Breisacher Str 86, D-79110 Freiburg, Germany
[2] Univ Freiburg, Med Ctr, Breisacher Str 86, D-79110 Freiburg, Germany
[3] Univ Freiburg, Clin Trials Unit, Fac Med, Elsasser Str 2, D-79110 Freiburg, Germany
[4] Univ Freiburg, Med Ctr, Elsasser Str 2, D-79110 Freiburg, Germany
[5] Univ Pecs, Clin Ctr, Med Sch, Cochrane Hungary, Pecs, Hungary
[6] Univ Freiburg, Inst Med Biometry & Stat, Fac Med, Stefan Meier Str 26, D-79104 Freiburg, Germany
[7] Univ Freiburg, Med Ctr, Stefan Meier Str 26, D-79104 Freiburg, Germany
关键词
Randomized controlled trials as topic; Registries; Access to information; Evidence-based medicine; Publishing; Systematic reviews as topic; Practice guidelines as topic; Knowledge translation; Health impact assessment; Clinical decision-making; INCREASING VALUE;
D O I
10.1186/s12874-021-01359-x
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background Healthcare decisions are ideally based on clinical trial results, published in study registries, as journal articles or summarized in secondary research articles. In this research project, we investigated the impact of academically and commercially sponsored clinical trials on medical practice by measuring the proportion of trials published and cited by systematic reviews and clinical guidelines. Methods We examined 691 multicenter, randomized controlled trials that started in 2005 or later and were completed by the end of 2016. To determine whether sponsorship/funding and place of conduct influence a trial's impact, we created four sub-cohorts of investigator initiated trials (IITs) and industry sponsored trials (ISTs): 120 IITs and 171 ISTs with German contribution compared to 200 IITs and 200 ISTs without German contribution. We balanced the groups for study phase and place of conduct. German IITs were funded by the German Research Foundation (DFG), the Federal Ministry of Education and Research (BMBF), or by another non-commercial research organization. All other trials were drawn from the German Clinical Trials Register or ClinicalTrials.gov. We investigated, to what extent study characteristics were associated with publication and impact using multivariable logistic regressions. Results For 80% of the 691 trials, results were published as result articles in a medical journal and/or study registry, 52% were cited by a systematic review, and 26% reached impact in a clinical guideline. Drug trials and larger trials were associated with a higher probability to be published and to have an impact than non-drug trials and smaller trials. Results of IITs were more often published as a journal article while results of ISTs were more often published in study registries. International ISTs less often gained impact by inclusion in systematic reviews or guidelines than IITs. Conclusion An encouraging high proportion of the clinical trials were published, and a considerable proportion gained impact on clinical practice. However, there is still room for improvement. For publishing study results, study registries have become an alternative or complement to journal articles, especially for ISTs. IITs funded by governmental bodies in Germany reached an impact that is comparable to international IITs and ISTs.
引用
收藏
页数:20
相关论文
共 37 条
[1]  
110th United States Congress, 2007, FOOD DRUG ADM AM ACT, P110
[2]  
AALEN OO, 1978, SCAND J STAT, V5, P141
[3]   Discontinuation and non-publication of randomised clinical trials supported by the main public funding body in Switzerland: a retrospective cohort study [J].
Amstutz, Alain ;
Schandelmaier, Stefan ;
Frei, Roy ;
Surina, Jakub ;
Agarwal, Arnav ;
Olu, Kelechi Kalu ;
Alturki, Reem ;
Von Niederhausern, Belinda ;
Von Elm, Erik ;
Briel, Matthias .
BMJ OPEN, 2017, 7 (07)
[4]   Barriers towards the publication of academic drug trials. Follow-up of trials approved by the Danish Medicines Agency [J].
Berendt, Louise ;
Petersen, Lene Grejs ;
Bach, Karin Friis ;
Poulsen, Henrik Enghusen ;
Dalhoff, Kim .
PLOS ONE, 2017, 12 (05)
[5]   Publication and non-publication of drug trial results: a 10-year cohort of trials in Norwegian general practice [J].
Braend, Anja Maria ;
Straand, Jorund ;
Jakobsen, Rune Bruhn ;
Klovning, Atle .
BMJ OPEN, 2016, 6 (04)
[6]   The impact of Cochrane Reviews: a mixed-methods evaluation of outputs from Cochrane Review Groups supported by the National Institute for Health Research [J].
Bunn, Frances ;
Trivedi, Daksha ;
Alderson, Phil ;
Hamilton, Laura ;
Martin, Alice ;
Pinkney, Emma ;
Iliffe, Steve .
HEALTH TECHNOLOGY ASSESSMENT, 2015, 19 (28) :1-+
[7]   Increasing value and reducing waste: addressing inaccessible research [J].
Chan, An-Wen ;
Song, Fujian ;
Vickers, Andrew ;
Jefferson, Tom ;
Dickersin, Kay ;
Gotzsche, Peter C. ;
Krumholz, Harlan M. ;
Ghersi, Davina ;
van der Worp, H. Bart .
LANCET, 2014, 383 (9913) :257-266
[8]   Publication and reporting of clinical trial results: cross sectional analysis across academic medical centers [J].
Chen, Ruijun ;
Desai, Nihar R. ;
Ross, Joseph S. ;
Zhang, Weiwei ;
Chau, Katherine H. ;
Wayda, Brian ;
Murugiah, Karthik ;
Lu, Daniel Y. ;
Mittal, Amit ;
Krumholz, Harlan M. .
BMJ-BRITISH MEDICAL JOURNAL, 2016, 352
[9]  
ClinicalTrials.gov, FIND RES STUD
[10]   Publication rates of research projects of an internal funding program of a university medical center in Germany: A retrospective study (2004-2013) [J].
Deutsch, Susanne ;
Reuter, Silke ;
Rose, Astrid ;
Tolba, Rene .
PLOS ONE, 2020, 15 (11)